每經AI快(kuai)訊，2023年(nian)5月(yue)22日，深(shen)(shen)交所向(xiang)未(wei)名(ming)醫(yi)藥（SZ 002581，收盤價(jia)：18.95元）發出問(wen)詢函：針對“你(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)年(nian)審(shen)機構深(shen)(shen)圳廣(guang)深(shen)(shen)會計師(shi)事(shi)(shi)務所（普通合(he)伙(huo)）對你(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)2022年(nian)財務報(bao)(bao)(bao)告出具了帶強(qiang)調(diao)事(shi)(shi)項(xiang)段(duan)保(bao)(bao)(bao)留(liu)(liu)意見(jian)的審(shen)計報(bao)(bao)(bao)告。保(bao)(bao)(bao)留(liu)(liu)意見(jian)涉及事(shi)(shi)項(xiang)為長(chang)(chang)期(qi)股權投資及投資收益的確(que)認、控股股東抵債資產(chan)價(jia)值(zhi)確(que)定，你(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)2019至(zhi)2021年(nian)度財務報(bao)(bao)(bao)表均(jun)因(yin)相(xiang)關(guan)(guan)事(shi)(shi)項(xiang)被出具保(bao)(bao)(bao)留(liu)(liu)意見(jian)的審(shen)計報(bao)(bao)(bao)告。強(qiang)調(diao)事(shi)(shi)項(xiang)為在時任董事(shi)(shi)會不知悉(xi)且未(wei)履行相(xiang)關(guan)(guan)審(shen)議程序情況下，公(gong)(gong)(gong)(gong)(gong)司(si)(si)原(yuan)董事(shi)(shi)長(chang)(chang)潘(pan)愛華、未(wei)名(ming)生物醫(yi)藥有(you)限(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)原(yuan)董事(shi)(shi)長(chang)(chang)兼總經理羅德順等人向(xiang)廈門市(shi)(shi)市(shi)(shi)場監督管理局提交登記（備(bei)案）申請，將杭州(zhou)強(qiang)新(xin)生物科技有(you)限(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)變更為子公(gong)(gong)(gong)(gong)(gong)司(si)(si)廈門未(wei)名(ming)股東，公(gong)(gong)(gong)(gong)(gong)司(si)(si)已(yi)就該(gai)事(shi)(shi)項(xiang)報(bao)(bao)(bao)案，目前公(gong)(gong)(gong)(gong)(gong)安機關(guan)(guan)正(zheng)在偵(zhen)查，杭州(zhou)強(qiang)新(xin)股權被凍結。因(yin)相(xiang)關(guan)(guan)杭州(zhou)強(qiang)新(xin)入股廈門未(wei)名(ming)事(shi)(shi)項(xiang)，廣(guang)深(shen)(shen)所對你(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)2022年(nian)內控出具了帶強(qiang)調(diao)事(shi)(shi)項(xiang)段(duan)無(wu)保(bao)(bao)(bao)留(liu)(liu)意見(jian)的審(shen)計報(bao)(bao)(bao)告。”等情況，深(shen)(shen)交所提出包括“請你(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)詳細說明截至(zhi)目前公(gong)(gong)(gong)(gong)(gong)司(si)(si)與北京(jing)科興生物制品(pin)有(you)限(xian)公(gong)(gong)(gong)(gong)(gong)司(si)(si)解決(jue)爭議的進展情況、你(ni)公(gong)(gong)(gong)(gong)(gong)司(si)(si)已(yi)采取和擬(ni)采取的措施。”等要求。

未名醫藥(yao)的董(dong)事長、總經理均是岳家(jia)霖，男，55歲，學(xue)歷背景為本(ben)科。

截至(zhi)發稿，未名醫(yi)藥市值為125億元(yuan)。

道(dao)達號（daoda1997）“個股趨勢”提醒：
1. 未名醫藥近30日內北向資金持股量增加227.11萬股，占流通股比例增加0.57%；
2. 近30日內無機構對未名醫藥進行調研。
更多個股趨(qu)勢(shi)信(xin)息，請搜索微信(xin)公眾號“道(dao)達號”，回復“查(cha)詢”，領取(qu)免費(fei)查(cha)詢權限！

每經頭條（nbdtoutiao）——

(記者 王曉波)

免責聲明(ming)：本文內(nei)容與數(shu)據僅供參考，不構成投資建議，使(shi)用前請核實。據此操作(zuo)，風險自擔。